Skip to main content

Table 3 Longitudinal data for patients with GHD or ISS with growth disorders and 1-year data

From: Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program

Mean ± SD

GHD

ISS

HSDS

Baseline

n = 72

− 1.94 ± 0.77

n = 19

−2.07 ± 0.77

Start of AIT

n = 70

− 0.92 ± 0.89

n = 19

− 0.87 ± 0.86

1 year after AIT

n = 72

− 0.62 ± 0.95

n = 19

−0.69 ± 0.83

BA/CA ratio

Baseline

n = 36

0.90 ± 0.11

n = 9

0.86 ± 0.19

Start of AIT

n = 56

0.96 ± 0.10

n = 17

0.99 ± 0.11

1 year after AIT

n = 43

0.93 ± 0.09

n = 16

0.96 ± 0.08

  1. AIT Aromatase inhibitor therapy, BA Bone age, CA Chronologic age, GHD Growth hormone deficiency, HSDS Height standard deviation score, ISS Idiopathic short stature
Back to article page

International Journal of Pediatric Endocrinology

ISSN: 1687-9856

Contact us